Considering the different prevalence of oncogenic driver mutations in NSCLC between Asian and white populations,17 we conducted another virtual validation of NCC-GP150 with established panels between TCGA NSCLC populations with and without EGFR (OMIM 131550) and/or KRAS (OMIM 190070) driver mutation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.